>>Signaling Pathways>> Others>>Gastrofensin AN 5 free base

Gastrofensin AN 5 free base

Catalog No.GC32051

4-페닐-테트라히드로이소퀴놀린 유도체인 Gastrofensin AN 5 유리 염기는 항궤양제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Gastrofensin AN 5 free base Chemical Structure

Cas No.: 89845-16-9

Size 가격 재고 수량
1mg
US$1,036.00
재고 있음
5mg
US$1,657.00
재고 있음
10mg
US$2,652.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Gastrofensin AN 5 free base, a 4-phenyl-tetrahydroisoquinoline derivative, is an antiulcer agent.

Gastrofensin AN 5 supresses the formation of ulcers in all experimental models. From the broad pharmacological studies of Gastrofensin AN 5 on this model it can be seen that even a dose of 0.100 mg/kg has a high antiulcer activity. The increase of the dose leads to a regular increase of the antiulcer activity, the highest suppression of the ulcer index being reaches at a dose of 1 mg/kg (86.15%). The comparative studies with Ranitidine and Cimetidine on the same experimental models of gastric ulcers show that Gastrofensin AN 5 possesses an antiulcer activity many times higher than that of the above-mentioned drugs[1].

[1]. Ivanova N, et al. A new class of antiulcer drugs. I. Antiulcer effect of AN5, a 4-phenyl-tetrahydroisoquinoline derivative, on different experimental models of ulcer in rats. Methods Find Exp Clin Pharmacol. 1990 Jul-Aug;12(6):401-10.

리뷰

Review for Gastrofensin AN 5 free base

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Gastrofensin AN 5 free base

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.